Tower Research Capital LLC TRC Has $134,000 Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Tower Research Capital LLC TRC increased its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 496.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,591 shares of the biotechnology company’s stock after acquiring an additional 4,654 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Arcturus Therapeutics were worth $134,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. BNP Paribas Arbitrage SA grew its position in Arcturus Therapeutics by 63.4% in the second quarter. BNP Paribas Arbitrage SA now owns 5,043 shares of the biotechnology company’s stock valued at $79,000 after acquiring an additional 1,956 shares during the period. Point72 Middle East FZE bought a new stake in Arcturus Therapeutics during the 4th quarter worth approximately $79,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Arcturus Therapeutics by 18.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,793 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 882 shares in the last quarter. Daiwa Securities Group Inc. raised its position in Arcturus Therapeutics by 23.8% in the 1st quarter. Daiwa Securities Group Inc. now owns 4,109 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 789 shares during the last quarter. Finally, Point72 Hong Kong Ltd boosted its stake in Arcturus Therapeutics by 3,653.2% in the second quarter. Point72 Hong Kong Ltd now owns 6,493 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 6,320 shares in the last quarter. 88.87% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ARCT has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $51.00 price target on shares of Arcturus Therapeutics in a report on Tuesday, August 15th. Wells Fargo & Company boosted their price objective on Arcturus Therapeutics from $35.00 to $45.00 in a report on Monday, July 17th. Guggenheim reaffirmed a “buy” rating on shares of Arcturus Therapeutics in a research note on Friday, July 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $54.00 price objective on shares of Arcturus Therapeutics in a report on Tuesday, August 22nd. Finally, William Blair began coverage on shares of Arcturus Therapeutics in a report on Monday, July 24th. They set an “outperform” rating and a $71.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $38.78.

Insider Activity at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 25,000 shares of the company’s stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $35.01, for a total value of $875,250.00. Following the completion of the transaction, the chief operating officer now directly owns 519,448 shares in the company, valued at approximately $18,185,874.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Keith C. Kummerfeld sold 6,968 shares of the business’s stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $35.00, for a total transaction of $243,880.00. Following the transaction, the insider now owns 950 shares in the company, valued at approximately $33,250. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Pad Chivukula sold 25,000 shares of the business’s stock in a transaction on Friday, July 14th. The shares were sold at an average price of $35.01, for a total transaction of $875,250.00. Following the transaction, the chief operating officer now directly owns 519,448 shares in the company, valued at $18,185,874.48. The disclosure for this sale can be found here. Insiders have sold a total of 36,968 shares of company stock valued at $1,262,880 over the last 90 days. 13.80% of the stock is owned by insiders.

Arcturus Therapeutics Trading Down 3.6 %

NASDAQ:ARCT opened at $30.35 on Friday. The stock has a market capitalization of $807.31 million, a PE ratio of 10.50 and a beta of 2.60. Arcturus Therapeutics Holdings Inc. has a 12 month low of $13.02 and a 12 month high of $37.75. The firm’s 50 day moving average is $31.01 and its 200 day moving average is $26.06.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($1.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($2.07). The firm had revenue of $10.52 million during the quarter, compared to analysts’ expectations of $71.05 million. Arcturus Therapeutics had a return on equity of 20.75% and a net margin of 30.36%. Research analysts predict that Arcturus Therapeutics Holdings Inc. will post -3.56 earnings per share for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.